Acute Myeloid Leukemia - Allogeneic Transplant Study (07-121)
CALGB 100103: A Phase II Study of Allogeneic Transplant for Older Patients with AML in First Morphologic complete remission using a Non-Myeloablative preparation regimen
Protocol ID
07-121
Protocol Description
The goal of this study is to replace the defective cells responsible for acute myeloid leukemia with normal cells from a non-affected donor. This experimental treatment is a new approach that attempts to stimulate a patient's own immune system to fight his/her disease.
Eligibility Criteria
Patients with acute myeloid leukemia and non-affected donors
Primary Investigator(s)
- Ruthee-Lu Bayer, MD